argenx SE (ARGX)

Etorro trading 970x250
argenx SE (ARGX) Logo

About argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands. Address: Willemstraat 5, Breda, Netherlands, 4811 AH

argenx SE News and around…

Latest news about argenx SE (ARGX) common stock and company :

This fund company was an early believer in Tesla — it’s now making these bets
18 Nov, 2021 FinancialContent

Baron funds took big stakes in Nvidia, Sea, Shopify and other companies in the third quarter.

Death Cross Looms Over argenx Investors
17 Nov, 2021 FinancialContent

If history is any guide, there may be trouble ahead for shares of argenx (NASDAQ:ARGX). A so-called "death cross" has formed on its ...

Best Stocks To Buy This Week? 3 Biotech Names To Know
31 Oct, 2021 FinancialContent
argenx (ARGX) Shares Cross Above 200 DMA
29 Oct, 2021 FinancialContent

In trading on Friday, shares of argenx SE (ARGX) crossed above their 200 day moving average of $305.30, changing hands as high as $306.36 per share. argenx SE shares are currently trading up about 7.4% on the day..

Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
29 Oct, 2021 FinancialContent

Upgrades For Preferred Bank (NASDAQ:PFBC), Stephens & Co. upgraded the previous rating of Equal-Weight to ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
29 Oct, 2021 FinancialContent

Gainers OptiNose (NASDAQ:OPTN) stock rose 17.74% to $3.11 during Friday's pre-market session. The company's ...

A Peek Into The Markets: US Stock Futures Down; Apple Posts Downbeat Sales
29 Oct, 2021 FinancialContent

Pre-open movers U.S. stock futures traded lower in early pre-market trade after the Dow Jones jumped more than 200 points in the ...

argenx SE (ARGX) Q3 2021 Earnings Call Transcript
28 Oct, 2021 FinancialContent

ARGX earnings call for the period ending September 30, 2021.

argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
28 Oct, 2021 Yahoo! Finance

– U.S. and Japan commercial teams fully staffed ahead of potential launches of efgartigimod in generalized myasthenia gravis (gMG) – – Signed partnership agreement with Medison for distribution of efgartigimod in Israel – – Wim Parys, M.D. to retire as Chief Medical Officer in March 2022 – – Management to host conference call today at 2:30 pm CEST (8:30 am ET) – October 28, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
21 Oct, 2021 Yahoo! Finance

October 21, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website

Analyst Ratings For argenx
19 Oct, 2021 FinancialContent

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: Bullish Somewhat ...

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
19 Oct, 2021 FinancialContent

Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ:INDP) from Hold to Buy. Indaptus Therapeutics ...

Where Do Hedge Funds Stand On argenx SE (ARGX)?
18 Oct, 2021 Yahoo! Finance

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
08 Oct, 2021 Yahoo! Finance

Additional data from Phase 3 ADAPT trial demonstrate consistent depth of response across first two treatment cycles as measured by minimal symptom expression Additional ADAPT data also show consistent disease score improvements by patient subgroup based on affected muscle domain or concomitant medication New analyses show efgartigimod treatment does not impact vaccine immune responseInitial data from MyRealWorld® MG research study highlight severity of disease and treatment burden of people livi

Expert Ratings For argenx
07 Oct, 2021 FinancialContent

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: Bullish Somewhat ...

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

Notable Two Hundred Day Moving Average Cross - ARGX
27 Sep, 2021 FinancialContent

In trading on Monday, shares of argenx SE (ARGX) crossed below their 200 day moving average of $305.24, changing hands as low as $302.79 per share. argenx SE shares are currently trading down about 1% on the day..

Medicine’s Golden Age Is Dawning. 10 Stocks to Play the Latest Innovations.
27 Sep, 2021 Yahoo! Finance

Our 2021 healthcare roundtable highlights the technologies and treatments changing the face of medicine, and the companies that could benefit.

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley
07 Sep, 2021 FinancialContent

Shares of Moderna Inc. rallied toward a fifth straight gain Tuesday, after Morgan Stanley analyst Matthew Harrison added nearly $150 to his price target on an increased outlook for the biotechnology company's COVID-19 vaccine sales.

What 4 Analyst Ratings Have To Say About argenx
07 Sep, 2021 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on argenx (NASDAQ:ARGX) stock. These analysts are typically employed by ...

Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021
07 Sep, 2021 FinancialContent

Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ:DOOO) from Market Perform to Outperform. For the ...

argenx to Present at Upcoming Investor Conferences
03 Sep, 2021 FinancialContent
ArgenxSE Shows Rising Price Performance With Jump To 81 RS Rating
02 Sep, 2021 FinancialContent

A Relative Strength Rating upgrade for ArgenxSE shows improving technical performance.

The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
25 Aug, 2021 FinancialContent

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stock Upgrades: ArgenxSE Shows Rising Relative Strength
25 Aug, 2021 FinancialContent

ArgenxSE shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
25 Aug, 2021 FinancialContent
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
04 Aug, 2021 FinancialContent
argenx SE (ARGX) Q2 2021 Earnings Call Transcript
30 Jul, 2021 FinancialContent

ARGX earnings call for the period ending June 30, 2021.

Recap: argenx Q2 Earnings
29 Jul, 2021 FinancialContent

Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly ...

argenx SE (ARGX) is a NASDAQ Common Stock listed in , ,

970x250